We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The rise of TIM‐3: A promising immune target in diffuse midline gliomas.
- Authors
Ausejo‐Mauleon, Iker; Nuin, Sara; Alonso, Marta M.
- Abstract
Diffuse midline gliomas (DMGs) are aggressive pediatric brain tumors that have historically been difficult to treat. However, recent research has identified TIM-3 as a promising therapeutic target for these tumors. TIM-3 is highly expressed in both tumor cells and immune cells in DMG patients, and blocking TIM-3 has been shown to prolong survival in preclinical models. This approach offers a different strategy compared to previous immune checkpoint therapies that have not been effective in DMGs. The results of this research support the initiation of clinical trials using anti-TIM-3 antibodies as a potential treatment for DMGs.
- Subjects
HEPATITIS A virus cellular receptors; BRAIN tumors; GLIOMAS; CENTRAL nervous system tumors; KILLER cells; MYELOID cells; IMMUNE checkpoint proteins
- Publication
Clinical & Translational Medicine, 2024, Vol 14, Issue 1, p1
- ISSN
2001-1326
- Publication type
Article
- DOI
10.1002/ctm2.1536